- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01193933
Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment
March 6, 2018 updated by: Elena N.Parovichnikova, National Research Center for Hematology, Russia
Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.
- evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the efficacy of its substitution by dexamethasone if blast count is 25% and more
- feasibility for adults of "no interruptions" protocol with 8 weeks induction and 14 weeks consolidation followed by 2-years maintenance.
- tolerability and efficacy in adults of the prolonged L-asparaginase application (total proposed dose 560.000 IU)
- feasibility and efficacy of autologous stem cell transplantation for T-cell ALL
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
- The blast count in b/m after 7 days of prednisolone >25% was shown in 64% of patients. The substitution of prednisolone by dexamethasone did not influence survival.
- "no interruptions" induction was performed in 48% of patients.
- In 19% of patients the L-asparaginase therapy was stopped due to toxicity.
- Autologous stem cell transplantation was done in 20% of T-cell ALL patients.
Study Type
Interventional
Enrollment (Anticipated)
321
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation
- Russian Acute Lymphoblastic Leukemia Study group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 55 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ph-negative precursors ALL
- age 15-55 years
- nontreated
- Eastern Cooperative Oncology Group criterion status 0-3
Exclusion Criteria:
- B-mature ALL
- Ph-positivity
- pretreatment
- Eastern Cooperative Oncology Group criterion status 4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of adult ALL patients who tolerated the non-interrupted treatment
Time Frame: 3 years
|
Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukemia efficacy in those subgroups
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity of prolonged L-asparaginase in adult patients
Time Frame: 3 years
|
Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukemia of those patients
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Valeri G Savchenko, Professor, National Research Center for Hematology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Parovichnikova EN, Troitskaya VV, Gavrilina OA, Sokolov AN, Kokhno AV, Klyasova GA, Kuzmina LA, Galstyan GM, Makhinya SA, Latyshkevich OA, Kaporskaya TS, Lapin VA, Chabaeva YA, Kulikov SM, Savchenko VG; for Russian Acute Lymphoblastic Leukemia group. The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009. Leuk Res. 2021 May;104:106536. doi: 10.1016/j.leukres.2021.106536. Epub 2021 Feb 14.
- Parovichnikova E, Troitskaya V, Sokolov A, Gavrilina O, Akhmerzaeva Z, Kuzmina L, Kliasova G, Chabaeva J, Kulikov S, Bondarenko S, Baranova O, Samoilova O, Kaplanov K, Minaeva N, Savchenko V; Russian Acute Lymphoblastic Leukemia Group. Can Less Intensive Chemotherapy and an Autotransplant Cure Adult T-Cell Acute Lymphoblastic Leukemia? Acta Haematol. 2020;143(2):131-139. doi: 10.1159/000502435. Epub 2019 Oct 9.
- Piskunova IS, Obukhova TN, Parovichnikova EN, Kulikov SM, Troitskaya VV, Gavrilina OA, Savchenko VG. Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. Ter Arkh. 2018 Aug 17;90(7):30-37. doi: 10.26442/terarkh201890730-37.
- Parovichnikova EN, Troitskaya VV, Sokolov AN, Bondarenko SN, Gavrilina OA, Baskhaeva GA, Biderman BV, Lukyanova IA, Kuz'mina LA, Klyasova GA, Kravchenko SK, Gribanova EO, Zvonkov EE, Akhmerzaeva ZK, Baranova OY, Kaporskaya TS, Ryltsova TV, Zotina EN, Zinina EE, Samoilova OS, Kaplanov KD, Gavrilova LV, Konstantinova TS, Lapin VA, Pristupa AS, Eluferyeva AS, Obukhova TN, Piskunova IS, Gal'tseva IV, Dvirnyk VN, Rusinov MA, Kulikov SM, Savchenko VG. [Adult B-cell acute lymphoblastic leukemias: Conclusions of the Russian prospective multicenter study ALL-2009]. Ter Arkh. 2017;89(7):10-17. doi: 10.17116/terarkh201789710-17. Russian.
- Parovichnikova EN, Kuzmina LA, Mendeleeva LP, Klyasova GA, Troitskaya VV, Sokolov AN, Akhmerzaeva ZK, Kravchenko SK, Gribanova EO, Zvonkov EE, Bondarenko SN, Baranova OY, Ryltsova TV, Gavrilova LV, Zinina EE, Pristupa AS, Kaporskaya TS, Minaeva NV, Samoilova OS, Konstantinova TS, Lapin VA, Kaplanov KD, Kryuchkova IV, Nizamutdinova AS, Klimovich AV, Borisenkova EA, Moskov VI, Gaponova TV, Obukhova TV, Galtseva IV, Rusinov MA, Kulikov SM, Savchenko VG. [Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study]. Ter Arkh. 2015;87(7):15-25. doi: 10.17116/terarkh201587715-25. Russian.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
December 1, 2016
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
August 31, 2010
First Submitted That Met QC Criteria
September 1, 2010
First Posted (Estimate)
September 2, 2010
Study Record Updates
Last Update Posted (Actual)
March 7, 2018
Last Update Submitted That Met QC Criteria
March 6, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALL-2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ph-negative Adult Acute Lymphoblastic Leukemia
-
Stanford UniversityNational Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia (ALL) | Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) | Recurrent Adult Acute Lymphoblastic Leukemia (ALL) | T-cell Adult Acute Lymphoblastic Leukemia (ALL)United States
-
Institute of Hematology and Blood Transfusion,...CZECRIN - Czech Clinical Research Infrastructure NetworkCompletedNewly Diagnosed | Lymphoblastic Leukemia, Acute, Adult | Ph Negative ALLCzechia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
The First Affiliated Hospital of Soochow UniversityRecruitingB Acute Lymphoblastic Leukemia | High Risk Acute Lymphoblastic Leukemia | Ph-Negative ALLChina
-
Institute of Hematology and Blood Transfusion,...CZECRIN - Czech Clinical Research Infrastructure NetworkSuspendedNewly Diagnosed | Acute Lymphoblastic Leukemia, Adult | Ph+ ALLCzechia
-
EDDC (Experimental Drug Development Centre), A*STAR...Chiltern International Inc.WithdrawnPh+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)United States, Singapore
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
AmgenRecruitingNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Japan, Australia, Denmark, Netherlands, Taiwan, Switzerland, Canada, France, United States, Austria, Italy, Spain, Sweden, Belgium, Hungary, Finland, Greece, Turkey, Portugal, Romania, Germany, Bulgaria, Mexico, United Kingdom
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on autologous HSCT
-
European Society for Blood and Marrow TransplantationRecruitingAutoimmune DiseasesFrance
-
European Society for Blood and Marrow TransplantationCompletedAutoimmune DiseasesFrance
-
National Research Center for Hematology, RussiaUnknownPrecursor Cell Lymphoblastic Leukemia-LymphomaRussian Federation
-
Nanfang Hospital, Southern Medical UniversityZhujiang HospitalCompletedAcute Myeloid Leukemia | Risk Stratification
-
Gary A Levy, O. Ont. MD. FRCP AGAFOttawa Hospital Research InstituteCompletedComplication of Transplanted Organ, NosCanada
-
Beijing GoBroad HospitalRecruitingRefractory/Relapsed Acute Myeloid LeukaemiaChina
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Ottawa Hospital Research InstituteMultiple Sclerosis Scientific Research FoundationCompleted
-
UMC UtrechtBoehringer Ingelheim; ZonMw: The Netherlands Organisation for Health Research... and other collaboratorsRecruitingSystemic Sclerosis | Scleroderma, Diffuse | Mycophenolate Mofetil | Scleroderma | Autologous Stem Cell Transplantation | Cyclophosphamide | Systemic Scleroses, Diffuse | Treatment StrategyItaly, Switzerland, Netherlands, Sweden, United Kingdom
-
Federal Research Institute of Pediatric Hematology...Physicians, Innovations, Science for Children FundRecruitingAcute Myeloid Leukemia, ChildhoodRussian Federation